Article
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Movement disorders : official journal of the Movement Disorder Society - 1 Mar 2023
Jennings Danna, Huntwork-Rodriguez Sarah, Vissers Maurits F J M, Daryani Vinay M, Diaz Dolores, Goo Marisa S, Chen John J, Maciuca Romeo, Fraser Kyle, Mabrouk Omar S, van de Wetering de Rooij Jeroen, Heuberger Jules A A C, Groeneveld Geert Jan, Borin Marie T, Cruz-Herranz Andrés, Graham Danielle, Scearce-Levie Kimberly, De Vicente Javier, Henry Anastasia G, Chin Peter, Ho Carole, Troyer Matthew D
Abstract excerpt
BACKGROUND: Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic approach for the treatment of Parkinson's disease (PD). OBJECTIVE: The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the potent, selective, CNS-penetrant LRRK2 inhibitor BIIB122 (DNL151) in healthy participants and patients with PD. METHODS: Two randomized, double-blind,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.